Denise Nebgen

Denise Nebgen is an Associate Professor in the Department of Gynecologic Oncology and Reproductive Medicine, Section of General Gynecology at the University of Texas MD Anderson Cancer Center.

Her research centers on cancer prevention and quality of life for female mutation carriers and survivors. She is the Principal Investigator on the first US Salpingectomy Pilot: ‘A Non-randomized Trial comparing Prophylactic Salpingectomy with Delayed Oophorectomy versus Risk Reducing Bilateral Salpingo-oophorectomy (RRSO) in BRCA mutation carriers’.

Denise is the Co-Principal Investigator on the WISP (Women Choosing Surgical Prevention) Trial: a Non-randomized US Trial, which compares salpingectomy to RRSO in mutation carriers at risk for ovarian cancer. WISP is a multi-institutional trial in 9 US sites that has accrued a total of 251 patients. In addition, she is the Co-Principal Investigator on the MAGENTA (Making Genetic Testing Accessible) Trial: An online-randomized clinical trial comparing standard approach telephone counseling to three alternative approaches including online educational video and online test results. A Stand Up to Cancer Grant sponsors the WISP and MAGENTA Trials. Going forward, she will be a Co-Investigator on the upcoming WISP/TUBA II International Salpingectomy Trail, which aims to enroll 3,000 patients.

Denise provides a consult service for women undergoing non-gynecologic cancer treatment who develop gynecologic problems. Where the focus is on prevention and treatment of abnormal uterine bleeding in female cancer patients undergoing high dose chemotherapy.